Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 May 4;23(1):178.
doi: 10.1186/s12957-025-03826-x.

Skeletal muscle index/systemic immune-inflammation index (SMI/SII) ratio predicts prognosis in patients with hepatocellular carcinoma

Affiliations
Multicenter Study

Skeletal muscle index/systemic immune-inflammation index (SMI/SII) ratio predicts prognosis in patients with hepatocellular carcinoma

Shu-Xian Li et al. World J Surg Oncol. .

Abstract

Background: Systemic inflammation and skeletal muscle are associated with prognosis in hepatocellular carcinoma (HCC). The prognostic value of a combination of skeletal muscle index (SMI) and systemic immune-inflammation index (SII) remains unclear. The present study aims to investigate the prognostic value of combined SMI and SII in predicting overall survival (OS) for HCCs after liver resection (LR) or transarterial chemoembolization (TACE).

Methods: This multi-institutional study included three retrospective datasets and one prospective dataset. The SMI/SII was calculated for each cohort. The performance of SMI/SII in predicting recurrence after LR was evaluated in the training cohort, and the optimal cut-off value was calculated. Based on optimal cut-off value, patients were stratified into low and high SMI/SII groups. Cox regression analysis were performed to determine the independent prognostic factors for poor OS. In prospective validation-3 cohort, peripheral blood samples were analyzed for correlation between SMI/SII and distribution of immune cells.

Results: A total of 1504 patients were included. The AUC of SMI/SII was 0.701. The OS was significantly better in the high SMI/SII group than that in the low SMI/SII group in the training, validation-1, validation-2 cohorts, and combined those three cohorts. Furthermore, low SMI/SII level was an independent prognostic factor for poor OS. Additionally, findings in validation-3 cohort indicated that patients with HCCs and high SMI/SII display anti-tumor attributes in their peripheral blood composition.

Conclusion: A decreased SMI/SII may be a distinct biomarker of unfavorable prognosis in patients with HCCs, which may be practical to develop personalized treatment strategies for HCC.

Keywords: Hepatocellular carcinoma; Nutrition status; Prognosis; Systemic inflammation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: The study was approved by the institutional review boards of the Second Xiangya Hospital of Central South University, the Affiliated Cancer Hospital of Guizhou Medical University, the Hunan Cancer Hospital and the Affiliated Hospital of Guizhou Medical University. This study was conducted in accordance with the Helsinki Declaration. The requirement of written informed consent was obtained for the prospective dataset only, while it was waived for the retrospective datasets owing to the study design. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of the study population (A, B)
Fig. 2
Fig. 2
Unenhanced axial CT scan before LR. A 48-year-old female with HCC in low SMI/SII group before (A) and after (B) segmentation of skeletal muscle. A 38-year-old male with HCC in high SMI/SII group before (C) and after (D) segmentation of skeletal muscle. The red outline represents the closed polygon drawn using the region of interest tool around the interior border of the skeletal muscle
Fig. 3
Fig. 3
Survival curves of the high and low SMI/SII groups in training (A before matching, B after matching), validation-1 (C before matching, D after matching), and validation-2 (E before matching, F after matching), as well as in the combined those three cohorts (G before matching, H after matching)
Fig. 4
Fig. 4
Distribution of immune cells in peripheral blood between high SMI/SII group and low SMI/SII group. CD3 + T cells were higher in the high SII/SMI group than low SII/SMI group (A). CD3 + CD4 + T cells were higher in the high SII/SMI group than low SII/SMI group (B). CD3 + CD8 + T cells were higher in the high SII/SMI group than low SII/SMI group (C). CD3-CD56 + NK cells were higher in the high SII/SMI group than low SII/SMI group (D). CD4 + CD25 + Tregs were lower in the high SII/SMI group than low SII/SMI group (E). Note: *P < 0.05; **P < 0.01; ***P < 0.001;

Similar articles

References

    1. Calderaro J, Ziol M, Paradis V, et al. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71:616–30. - PubMed
    1. Bao Y, Li JX, Zhou P, et al. Identifying proliferative hepatocellular carcinoma at pretreatment CT: implications for therapeutic outcomes after transarterial chemoembolization. Radiology. 2023;308:e230457. - PubMed
    1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:1. - PubMed
    1. Feng ZC, Li HL, Liu QY, et al. CT radiomics to predict macrotrabecular-massive subtype and immune status in hepatocellular carcinoma. Radiology. 2023;307:e221291. - PubMed
    1. Yau T, Tang VYF, Yao TJ, et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146:1691–700. - PubMed

Publication types

MeSH terms

LinkOut - more resources